NO20072659L - Pharmaceutical preparations comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of type I diabetes mellitus, obesity and related conditions - Google Patents

Pharmaceutical preparations comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of type I diabetes mellitus, obesity and related conditions

Info

Publication number
NO20072659L
NO20072659L NO20072659A NO20072659A NO20072659L NO 20072659 L NO20072659 L NO 20072659L NO 20072659 A NO20072659 A NO 20072659A NO 20072659 A NO20072659 A NO 20072659A NO 20072659 L NO20072659 L NO 20072659L
Authority
NO
Norway
Prior art keywords
treatment
type
diabetes mellitus
obesity
cannabinoid receptor
Prior art date
Application number
NO20072659A
Other languages
Norwegian (no)
Inventor
Peter-Colin Gregory
Harald Waldeck
Jochen Antel
Michael Firnges
Josephus Hubertus Maria Lange
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/055534 external-priority patent/WO2006045799A2/en
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20072659L publication Critical patent/NO20072659L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Kombinasjonsterapi for diabetes mellitus type I og/eller overvekt og dens ledsagende og/eller sekundære sykdommer eller tilstander, særlig det metabolske syndrom og/eller syndrom X, og/eller diabetes mellitus type II, ved å administrere en kombinasjon av minst én KATP-kanalåpner som et første aktivt middel, og minst én CB1-kannabinoidreseptorantagonist som et andre aktivt middel. Oppfinnelsen er videre rettet mot slik ny kombinasjonsterapi hvor en dobbeltvirkende forbindelse med kombinerte KATP-kanalåpnings- og CB1-antagonistiske egenskaper anvendes. Oppfinnelsen vedrører også nye farmasøytiske preparater som omfatter KATP-kanalåpnere og CB1-antagonister, og anvendelsen av de farmasøytiske preparatene ved behandling, forsinket progresjon, forsinket inntreden og/eller inhibering av diabetes mellitus type I, og profylakse og behandling av overvekt, samt profylakse, behandling, forsinket inntreden og/eller inhibering av dens ledsagende og/eller sekundære sykdommer eller tilstander, særlig det metabolske syndrom og/eller syndrom X, og/eller diabetes mellitus type II hos pattedyr og mennesker. Oppfinnelsen er videre rettet mot slike nye farmasøytiske preparater som omfatter en dobbeltvirkende forbindelse med kombinerte KATP-kanalåpnings- og CB1-antagonistiske egenskaper.Combination therapy for diabetes mellitus type I and / or obesity and its attendant and / or secondary diseases or conditions, in particular metabolic syndrome and / or syndrome X, and / or diabetes mellitus type II, by administering a combination of at least one KATP channel opener as a first active agent, and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such new combination therapy where a double-acting compound with combined KATP channel opening and CB1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising KATP channel openers and CB1 antagonists, and the use of the pharmaceutical compositions in treatment, delayed progression, delayed onset and / or inhibition of type I diabetes mellitus, and prophylaxis and treatment of obesity, and prophylaxis, treatment, delayed onset and / or inhibition of its concomitant and / or secondary diseases or conditions, particularly the metabolic syndrome and / or syndrome X, and / or mammalian type II diabetes in humans and humans. The invention is further directed to such novel pharmaceutical compositions which include a double-acting compound with combined KATP channel opening and CB1 antagonistic properties.

NO20072659A 2004-10-25 2007-05-24 Pharmaceutical preparations comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of type I diabetes mellitus, obesity and related conditions NO20072659L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62107704P 2004-10-25 2004-10-25
EP04105265 2004-10-25
US65162505P 2005-02-11 2005-02-11
PCT/EP2005/055534 WO2006045799A2 (en) 2004-10-25 2005-10-25 Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions

Publications (1)

Publication Number Publication Date
NO20072659L true NO20072659L (en) 2007-05-24

Family

ID=36000901

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072659A NO20072659L (en) 2004-10-25 2007-05-24 Pharmaceutical preparations comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of type I diabetes mellitus, obesity and related conditions

Country Status (3)

Country Link
KR (1) KR20070070226A (en)
IL (1) IL182415A0 (en)
NO (1) NO20072659L (en)

Also Published As

Publication number Publication date
IL182415A0 (en) 2007-07-24
KR20070070226A (en) 2007-07-03

Similar Documents

Publication Publication Date Title
WO2006045799A3 (en) Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
Cadegiani Repurposing existing drugs for COVID-19: an endocrinology perspective
MX2023007192A (en) PRMT5 INHIBITORS.
CR20220371A (en) GLP-1 HETEROCYCLIC AGONISTS
MX2022010011A (en) Novel prmt5 inhibitors.
NO20084403L (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of II-beta-hydroxysteroid dehydrogenase I
NO20084318L (en) Inhibitors of II-beta-hydroxysteroid dehydrogenase I
MX2024002467A (en) Combination therapies.
NO20071584L (en) New pharmaceutical compositions comprising 4- (4- (3- (4-chloro-3-trifluoromethylphenyl) urido) -3-fluorophenoxy) pyridine-2-carboxylic acid for the treatment of hyperproliferative disorders
BRPI0812504B8 (en) compound for prophylaxis or treatment of cannabinoid receptor-associated disease or condition in mammalian subject
NO20072542L (en) Pyrimidine derivative condensed with non-aromatic ring
WO2006014665A3 (en) Arylpyrrolidine derivatives as nk-1/ssri antagonists
NO20084489L (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
NZ756749A (en) Methods and compositions comprising purified recombinant polypeptides
NO20072804L (en) Anthranilamide pyridine ureas as VEGF receptor kinase inhibitors
CY1109624T1 (en) Substituted thiophene derivatives as glycogen receptor antagonists, preparations and therapeutic uses
NO20092374L (en) Compounds that have both angiotensin II receptor antagonism and PPARγ activating activities
EP2607348A3 (en) Plasminogen Activator Inhibitor-1 Inhibitor
ZA202212128B (en) Combination of alcaftadine and a corticosteroid
MX345032B (en) Selective ep4 receptor agonistic substance for treatment of cancer.
NO20061737L (en) Amino-substituted erylamino B2 adrenergic receptor agonists
Omboni et al. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
Ordonez et al. Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses
US12350244B2 (en) MEK-inhibitor for the treatment of viral and bacterial infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application